Kymera Therapeutics Inc (KYMR)
33.29
-1.58
(-4.53%)
USD |
NASDAQ |
Jun 14, 16:00
33.25
-0.04
(-0.12%)
After-Hours: 20:00
Kymera Therapeutics Revenue (Quarterly): 10.29M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 10.29M |
| December 31, 2023 | 47.88M |
| September 30, 2023 | 4.728M |
| June 30, 2023 | 16.51M |
| March 31, 2023 | 9.466M |
| December 31, 2022 | 16.14M |
| September 30, 2022 | 9.551M |
| June 30, 2022 | 11.51M |
| March 31, 2022 | 9.622M |
| December 31, 2021 | 15.28M |
| Date | Value |
|---|---|
| September 30, 2021 | 20.34M |
| June 30, 2021 | 18.52M |
| March 31, 2021 | 18.70M |
| December 31, 2020 | 12.78M |
| September 30, 2020 | 14.53M |
| June 30, 2020 | 3.288M |
| March 31, 2020 | 3.428M |
| December 31, 2019 | 1.833M |
| September 30, 2019 | 0.95M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.95M
Minimum
Sep 2019
47.88M
Maximum
Dec 2023
12.91M
Average
11.51M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
| SELLAS Life Sciences Group Inc | -- |
| Iovance Biotherapeutics Inc | 0.715M |
| Immunic Inc | -- |
| Protagonist Therapeutics Inc | 254.95M |
| Ovid Therapeutics Inc | 0.148M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -48.56M |
| Total Expenses (Quarterly) | 63.19M |
| EPS Diluted (Quarterly) | -0.69 |
| Enterprise Value | 1.522B |
| Profit Margin (Quarterly) | -472.0% |
| Earnings Yield | -7.54% |
| Normalized Earnings Yield | -7.331 |